Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice
Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that evolve to escape spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or Main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy did not eliminate SARS-CoV-2 in mice. However, targeting two viral enzymes by combining molnupiravir with nirmatrelvir resulted in superior efficacy and virus clearance. Furthermore, combining molnupiravir with Caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma yielded rapid virus clearance and 100% survival. Thus, our study provides insights into treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal.
| Errataetall: |
UpdateIn: iScience. 2024 Jan 30;27(3):109049. - PMID 38361624 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 01. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ullah, Irfan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Electronic UpdateIn: iScience. 2024 Jan 30;27(3):109049. - PMID 38361624 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.05.31.543159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358995116 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358995116 | ||
| 003 | DE-627 | ||
| 005 | 20240411232053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.05.31.543159 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM358995116 | ||
| 035 | |a (NLM)37398307 | ||
| 035 | |a (PII)2023.05.31.543159 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ullah, Irfan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: iScience. 2024 Jan 30;27(3):109049. - PMID 38361624 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that evolve to escape spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or Main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy did not eliminate SARS-CoV-2 in mice. However, targeting two viral enzymes by combining molnupiravir with nirmatrelvir resulted in superior efficacy and virus clearance. Furthermore, combining molnupiravir with Caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma yielded rapid virus clearance and 100% survival. Thus, our study provides insights into treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Escudie, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Scandale, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Gilani, Zoela |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Gaudette, Fleur |e verfasserin |4 aut | |
| 700 | 1 | |a Mowbray, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Fraisse, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Bazin, Renée |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Mothes, Walther |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Priti |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Uchil, Pradeep D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 01. Juni |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.05.31.543159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 06 | ||